Study of EGFR-mutated lung cancer evolution and markers
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with non-small cell lung cancer.
- Your cancer has an EGFR mutation (a specific genetic change).
- You can provide a tumor tissue sample (from a past biopsy or new one).
- You are in generally good health (able to care for yourself, no serious heart, liver, kidney, or active infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This trial uses your tumor sample to guide personalized treatment decisions for certain lung cancers. It may help by matching you to a more targeted plan based on genetic testing and your prior treatment history.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
This trial collects information from people with a specific type of advanced lung cancer to create a comparison group. It helps researchers understand how well new treatments work without giving any experimental medicine.
This study looks at how lung cancer changes over time by analyzing tumor tissue and blood. It may help researchers understand what drives cancer relapse after early-stage surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.